Wall Street analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to announce ($0.25) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Celldex Therapeutics’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.23). Celldex Therapeutics reported earnings of ($0.29) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.8%. The company is expected to issue its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Celldex Therapeutics will report full-year earnings of ($1.06) per share for the current financial year, with EPS estimates ranging from ($1.12) to ($0.98). For the next financial year, analysts forecast that the business will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.12) to ($0.82). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. During the same period in the previous year, the firm earned ($0.32) EPS. The business’s revenue for the quarter was up 175.5% on a year-over-year basis.

A number of research firms have issued reports on CLDX. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Tuesday, July 11th. Aegis restated a “buy” rating on shares of Celldex Therapeutics in a research report on Thursday, June 29th. ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 3rd. BidaskClub downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, Jefferies Group LLC restated a “hold” rating and set a $3.50 target price (down from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, May 11th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $7.32.

COPYRIGHT VIOLATION WARNING: “” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.watchlistnews.com/1494546-2/1494546.html.

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 2.47 on Wednesday. The company’s market capitalization is $317.00 million. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $5.02. The company has a 50 day moving average of $2.46 and a 200-day moving average of $2.99.

Hedge funds have recently made changes to their positions in the company. Meditor Group Ltd increased its stake in shares of Celldex Therapeutics by 39.9% in the second quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock valued at $14,326,000 after buying an additional 1,654,100 shares during the period. Norges Bank acquired a new position in shares of Celldex Therapeutics during the fourth quarter valued at $1,248,000. Bank of New York Mellon Corp boosted its position in shares of Celldex Therapeutics by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock valued at $1,943,000 after buying an additional 5,616 shares in the last quarter. State of Wisconsin Investment Board boosted its position in shares of Celldex Therapeutics by 206.3% in the first quarter. State of Wisconsin Investment Board now owns 750,000 shares of the biopharmaceutical company’s stock valued at $2,708,000 after buying an additional 505,138 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its position in shares of Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 63.88% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.